Zymergen Inc. (NasdaqGS:ZY) acquired Lodo Therapeutics Corp. from Accelerator Life Science Partners I, managed by Accelerator Life Science Partners and others for $25.9 million.
Zymergen Inc. (NasdaqGS:ZY) completed the acquisition of Lodo Therapeutics Corp. from Accelerator Life Science Partners I, managed by Accelerator Life Science Partners and others for $25.9 million on May 16, 2021. The purchase price for the acquisition was $25.3 million, substantially all of which was non-cash consideration. The non-cash consideration consisted of 774,402 shares of the Zymergen's common stock. As part of the acquisition, Zymergen acquired $1.8 million of cash and cash equivalents.